Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System

M. Fuller, Kenneth M Shermock, P. Russo, M. Secic, R. Dirani, S. Vallow, S. Flanders

Research output: Contribution to journalArticle


Objective: To examine hospitalisation rates and resource utilisation following initiation of risperidone long-acting therapy (RLAT) among US veterans with schizophrenia. Methods: Encounter data were analysed from the Ohio Veterans Affairs (VA) Healthcare System. Adult patients (schizophrenia or schizoaffective disorder) with ≥1 medical or hospital visits with a diagnosis code of 295.xx, continuous enrolment from January 2003 through January 2006, and ≥4 injections of RLAT were selected. Analyses compared psychiatric-related resource utilisation pre- and post-exposure to RLAT; each patient served as his/her own control. The pre-exposure and post-exposure periods defined were equal in duration (e.g., a 6-month post-exposure period was matched with a 6-month pre-exposure period). Descriptive and comparative analyses (paired t tests, McNemar's test) were performed. Results: Patients (n106) were 51.9 years old (±10.2), male (93%), white (73%) and received on average 14 RLAT doses (±9.7; range, 447 injections) over 309 days (±196; range, 42737 days). Most experienced a psychiatric-related hospitalisation prior to initiation; less than half experienced hospitalisation after initiation (75% vs. 42%; p

Original languageEnglish (US)
Pages (from-to)317-324
Number of pages8
JournalJournal of Medical Economics
Issue number4
Publication statusPublished - Dec 2009



  • Hospitalisation
  • Resource utilisation
  • Risperidone long-acting therapy
  • Schizophrenia
  • Veterans affairs

ASJC Scopus subject areas

  • Health Policy

Cite this